Establishment of rat model for aspiration pneumonia and potential mechanisms

Abstract

Background: Aspiration pneumonia is a severe health concern, particularly for ICU patients with impaired airway defenses. Current animal models fail to fully replicate the condition, focusing solely on chemical lung injury from gastric acid while neglecting pathogen-induced inflammation. This gap hinders research on pathogenesis and treatment, creating an urgent need for a clinically relevant model. This study aimed to develop an improved rat model of aspiration pneumonia by combining hydrochloric acid (HCl) and lipopolysaccharide (LPS) administration.

Methods: Specific pathogen-free Sprague Dawley rats underwent intratracheal instillation of HCl and LPS. Techniques included rat weight measurement, tracheal intubation, pulmonary function monitoring, lung tissue sampling with HE staining and scoring, bronchoalveolar lavage fluid (BALF) sampling, protein and inflammatory cytokine analysis via BCA and ELISA, BALF pH determination, Evans Blue dye assessment, blood gas analysis, FITC-dextran leakage, Western blotting, electron microscopy, survival analysis, and transcriptome sequencing with bioinformatics. Statistical analysis was performed using GraphPad Prism.

Results: The optimal model involved instillation of 1.5 μL/g.wt HCl (pH = 1) followed by 20 μg/g.wt LPS after 1 h. This model reproduced acute lung injury, including tissue damage, pulmonary microvascular dysfunction, inflammatory responses, hypoxemia, and impaired pulmonary ventilation, with recovery observed at 72 h. PANoptosis was confirmed, characterized by increased markers. Concentration-dependent effects of HCl and LPS on lung damage were identified, alongside cytokine elevation and microvascular dysfunction.

Conclusions: This optimized model closely mimics clinical aspiration pneumonia, providing a valuable tool for studying pathophysiology and therapeutic strategies.

Keywords

acute lung injury / aspiration / disease models / pneumonia

References

[1] Raghavendran K, Nemzek J, Napolitano LM, Knight PR. Aspiration-induced lung injury. Crit Care Med. 2011; 39(4): 818-826.

[2] Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B. Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology. 1993; 78(6): 1145-1151.

[3] Knight PR, Davidson BA, Nader ND, et al. Progressive, severe lung injury secondary to the interaction of insults in gastric aspiration. Exp Lung Res. 2004; 30(7): 535-557.

[4] Košutova P, Mikolka P. Aspiration syndromes and associated lung injury: incidence, pathophysiology and management. Physiol Res. 2021; 70(Suppl4): S567-S583.

[5] Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001; 344(9): 665-671.

[6] Mandell LA, Niederman MS. Aspiration Pneumonia. N Engl J Med. 2019; 380(7): 651-663.

[7] Mier L, Dreyfuss D, Darchy B, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med. 1993; 19(5): 279-284.

[8] Davidson BA, Knight PR, Helinski JD, Nader ND, Shanley TP, Johnson KJ. The role of tumor necrosis factor-alpha in the pathogenesis of aspiration pneumonitis in rats. Anesthesiology. 1999; 91(2): 486-499.

[9] Davidson BA, Knight PR, Wang Z, et al. Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates. Am J Physiol Lung Cell Mol Physiol. 2005; 288(4): L699-L708.

[10] Binz J, Heft M, Robinson S, Jensen H, Newton J. Utilizing procalcitonin in a clinical setting to help differentiate between aspiration pneumonia and aspiration pneumonitis. Diagn Microbiol Infect Dis. 2023; 105(1): 115821.

[11] Bless NM, Huber-Lang M, Guo RF, et al. Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J Immunol. 2000; 164(5): 2650-2659.

[12] Manderscheid PA, Bodkin RP, Davidson BA, Jensen E, Russo TA, Knight PR. Bacterial clearance and cytokine profiles in a murine model of postsurgical nosocomial pneumonia. Clin Diagn Lab Immunol. 2004; 11(4): 742-751.

[13] Yu D, Bei YY, Li Y, et al. In vitro the differences of inflammatory and oxidative reactions due to sulfur mustard induced acute pulmonary injury underlying intraperitoneal injection and intratracheal instillation in rats. Int Immunopharmacol. 2017; 47: 78-87.

[14] Yoon SH, Song MK, Kim DI, et al. Comparative study of lung toxicity of E-cigarette ingredients to investigate E-cigarette or vaping product associated lung injury. J Hazard Mater. 2023; 445: 130454.

[15] Liu X, Su S, Xia L, et al. Lysophosphatidylcholine 14:0 alleviates lipopolysaccharide-induced acute lung injury via protecting alveolar epithelial barrier by activation of Nrf2/HO-1 pathway. J Inflamm Res. 2024; 17: 10533-10546.

[16] Ma M, Wang K, Yang YH, et al. Influence of Tongfu Xiefei Guanchang solution on intestinal barrier and intestinal flora of rats with acute lung injury based on p38 MAPK/MLCK signaling pathway. Zhongguo Zhong Yao Za Zhi. 2024; 49(21): 5919-5931.

[17] Xiao J, Hou F, Wang H, et al. Monocyte-derived macrophages induce alveolar macrophages death via TNF-α in acute lung injury. Immun Inflamm Dis. 2024; 12(12): e70081.

[18] Kulkarni HS, Lee JS, Bastarache JA, et al. Update on the features and measurements of experimental acute lung injury in animals: an official American Thoracic Society workshop report. Am J Respir Cell Mol Biol. 2022; 66(2): e1-e14.

[19] Zhou J, Peng Z, Wang J. Trelagliptin alleviates lipopolysaccharide (LPS)-induced inflammation and oxidative stress in acute lung injury mice. Inflammation. 2021; 44(4): 1507-1517.

[20] Wang Y, Wang Y, Ma J, et al. YuPingFengSan ameliorates LPS-induced acute lung injury and gut barrier dysfunction in mice. J Ethnopharmacol. 2023; 312: 116452.

[21] Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342(18): 1301-1308.

[22] Carlino MV, Guarino M, Izzo A, et al. Arterial blood gas analysis utility in predicting lung injury in blunt chest trauma. Respir Physiol Neurobiol. 2020; 274: 103363.

[23] Chen H, Lin X, Yi X, et al. SIRT1-mediated p53 deacetylation inhibits ferroptosis and alleviates heat stress-induced lung epithelial cells injury. Int J Hyperth. 2022; 39(1): 977-986.

[24] Li J, Deng SH, Li J, et al. Obacunone alleviates ferroptosis during lipopolysaccharide-induced acute lung injury by upregulating Nrf2-dependent antioxidant responses. Cell Mol Biol Lett. 2022; 27(1): 29.

[25] Liu C, Yin Z, Feng T, Zhang M, Zhou Z, Zhou Y. An integrated network pharmacology and RNA-Seq approach for exploring the preventive effect of Lonicerae japonicae flos on LPS-induced acute lung injury. J Ethnopharmacol. 2021; 264: 113364.

[26] Chen S, Jiang J, Li T, Huang L. PANoptosis: mechanism and role in pulmonary diseases. Int J Mol Sci. 2023; 24(20): 15343.

[27] Chimenti L, Morales-Quinteros L, Puig F, et al. Comparison of direct and indirect models of early induced acute lung injury. Intensive Care Med Exp. 2020; 8(Suppl 1): 62.

[28] Colunga Biancatelli RML, Solopov P, Dimitropoulou C, Gregory B, Day T, Catravas JD. The heat shock protein 90 inhibitor, AT13387, protects the Alveolo-capillary barrier and prevents HCl-induced chronic lung injury and pulmonary fibrosis. Cells. 2022; 11(6): 1046.

[29] Marinova M, Solopov P, Dimitropoulou C, Colunga Biancatelli RML, Catravas JD. Post-treatment with a heat shock protein 90 inhibitor prevents chronic lung injury and pulmonary fibrosis, following acute exposure of mice to HCl. Exp Lung Res. 2020; 46(6): 203-216.

[30] Mokrá D. Acute lung injury—from pathophysiology to treatment. Physiol Res. 2020; 69(Suppl 3): S353-S366.

[31] Wang Y, Kanneganti TD. From pyroptosis, apoptosis and necroptosis to PANoptosis: a mechanistic compendium of programmed cell death pathways. Comput Struct Biotechnol J. 2021; 19: 4641-4657.

[32] You YP, Yan L, Ke HY, et al. Baicalin inhibits PANoptosis by blocking mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly in macrophages. Acta Pharmacol Sin. 2024; 46: 430-447.

[33] Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev. 2020; 297(1): 26-38.

[34] Malireddi RKS, Sharma BR, Bynigeri RR, Wang Y, Lu J, Kanneganti TD. ZBP1 drives IAV-induced NLRP3 Inflammasome activation and lytic cell death, PANoptosis, independent of the necroptosis executioner MLKL. Viruses. 2023; 15(11): 2141.

[35] Lei X, Chen Y, Lien E, Fitzgerald KA. MLKL-driven Inflammasome activation and Caspase-8 mediate inflammatory cell death in influenza a virus infection. MBio. 2023; 14(2): e0011023.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.